Shares of Insilico Medicine (03696) rallied nearly 9% during Tuesday morning trading, with the stock climbing 8.69% to HK$51.80 at the time of writing, on turnover of HK$207 million.

The surge came after the company announced on September 7, via its official WeChat account, that it had signed a strategic cooperation agreement with MobiDrop. The partnership is centered on deep collaboration around the production, integration, and application of high-quality, traceable, and AI-ready single-cell data.

Under the agreement, the large-scale multi-omics data generated by MobiDrop will be systematically channeled into Insilico Medicine's Pharma.AI platform data repository. This data will provide critical training, validation, and model iteration support for the company's core generative biology platform, PandaOmics, as well as its newly launched multi-agent-driven Virtual Aging Cell (VAC) platform.

It is worth noting that Insilico Medicine had previously released an interactive preview of its VAC platform, powered by a "multi-agent cluster," in August 2026. Through this new collaboration, the two parties will jointly establish training and evaluation datasets tailored for "same-cell multimodal models." These datasets will provide a real, traceable wet-lab reference framework for the VAC platform, accelerating the transition of AI virtual cells from merely "understanding biology" to actively "intervening in cell fate."

Ultimately, the partnership aims to achieve large-scale implementation of a closed-loop dry-wet experiment system at single-cell resolution.